Honeywell Automation India Limited today announced that its Honeywell Building Solutions business has secured a contract from Reliance Life Sciences (RLS)  for building management and safety technology.

Honeywell will assist Reliance Life Sciences with supply, installation, testing and commissioning of integrated building management command and control and environment monitoring systems. It will also integrate its current fire detection and voice evacuation systems with Honeywell Connected Life Safety Services (CLSS), for its multiple plants at Nashik, Maharashtra, India. Honeywell’s contract with Reliance Life Sciences encompasses a seven-year annual maintenance support commitment, providing sustained operational excellence.

“Honeywell is proud to partner with Reliance Life Sciences in its automation journey.  Under the project, we will integrate and deploy Honeywell’s Enterprise Buildings Integrator (EBI) Command Control Suite and CLSS making it a significant win in the pharmaceutical vertical. Our superior building management and safety technology will enhance the overall safety, efficiency and sustainability across RLS” said Ashish Modi, President, Honeywell India.

Honeywell's EBI Command and Control Suite empowers Reliance Life Sciences with a comprehensive overview of its building management and security systems that is seamlessly consolidated within a unified dashboard. This integration allows Reliance Life Sciences to oversee numerous operations and stations across a 160-acre facility more efficiently.

Honeywell's CLSS cloud platform integrates data for secure, compliant, and efficient fire system management, offering connectivity, intelligence, and remote monitoring.

"Reliance Life Sciences has had a long-standing relationship with Honeywell in building- management technology solutions and is pleased to graduate this to the next-generation technology of connected life-safety services, and on a larger scale involving multiple manufacturing facilities in its second life sciences campus project at Nashik.” said K.V. Subramaniam, President, Reliance Life Sciences.